文献速递生殖医学

非男性因素不孕夫妇中ICSI并不优于常规IVF:一项PGT-A前瞻性自身对照研究

Intracytoplasmic sperm injection is not superior to conventional IVF in couples with non-male factor infertility and preimplantation genetic testing for aneuploidies (PGT-A).
PubMed 文献 · Hum Reprod · 2020-01-01

该单中心前瞻性预试验纳入30对非男性因素不孕的阿拉伯夫妇,将同胞卵母细胞随机分配至常规IVF或ICSI,经PGT-A后比较整倍体囊胚率。结果显示两种受精方式的整倍体率无显著差异,且每对夫妇均至少获得一枚可移植整倍体囊胚。

要点

  • 非男性因素不孕行PGT-A时,常规IVF与ICSI获得的整倍体囊胚数相当。
  • ICSI组卵母细胞退化率显著更高,IVF组异常受精(≥3原核)显著更高。
  • 两组正常受精率、第3天优质胚胎数、囊胚形成率及活检囊胚数均无显著差异。

核心结论

  • 在非男性因素不孕且行PGT-A的夫妇中,常规IVF可安全应用,因为IVF与ICSI产生的整倍体囊胚数相等。

研究设计与样本

  • 同胞卵母细胞一半分配至常规IVF(n=283),另一半分配至ICSI(n=285),所有胚胎用time-lapse培养至第5、6或7天行滋养层活检及NGS。

主要发现

  • 每周期正常受精率IVF为6.1±3.8(64.0%),ICSI为6.3±3.5(65.4%),P=0.609。
  • 卵母细胞退化率ICSI显著高于IVF(0.7±0.8 vs 0.1±0.3,P=0.0003)。
  • 异常受精(≥3原核)率IVF显著高于ICSI(0.9±1.2 vs 0.2±0.4,P=0.005)。
  • 第3天优质胚胎率(74% vs 78%,P=0.467)、第5天囊胚形成率(80.4% vs 70.8%,P=0.076)及每周期活检囊胚总数(4.0±2.8 vs 3.9±2.5,P=0.774)均无显著差异。
  • 整倍体率IVF为49.8%、ICSI为44.1%(P=0.755;OR 1.05664 [0.75188-1.48494]),每周期整倍体囊胚数(2.0±1.8 vs 1.9±1.7,P=0.808)无显著差异,所有夫妇均至少有一枚整倍体囊胚可移植。

关键数值与推荐

  • 纳入标准:女性年龄18-40岁、BMI≤30 kg/m2、取卵后至少10个COCs、取卵当日新鲜精液浓度和活力正常(WHO标准)。
  • 主要终点为同胞卵母细胞来源囊胚的整倍体率。

临床怎么用

  • 对于非男性因素不孕且计划行PGT-A的夫妇,可考虑使用常规IVF替代ICSI,以避免ICSI相关卵母细胞退化。
  • 需注意常规IVF可能增加异常受精(≥3原核)的风险。

局限性

  • 本研究为预试验,样本量有限(30对夫妇、568个COCs),且患者卵巢反应正常。
  • 结果不应外推至其他患者群体。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does the insemination method impact the euploidy outcome in couples with non-male factor infertility? SUMMARY ANSWER: Conventional IVF can be applied in cycles with preimplantation genetic testing for aneuploidies (PGT-A), as both IVF and ICSI generate equal numbers of euploid blastocysts. WHAT IS KNOWN ALREADY: Ever since its introduction, the popularity of ICSI has increased tremendously, even in couples with non-male factor infertility. The use of conventional IVF is a contraindication for couples undergoing PGT to ensure monospermic fertilisation and to eliminate potential paternal contamination from extraneous sperm attached to the zona pellucida. Despite this, it has recently been shown that sperm DNA fails to amplify under the conditions used for trophectoderm biopsy samples. STUDY DESIGN, SIZE, DURATION: This single-centre prospective pilot study included 30 couples between November 2018 and April 2019. PARTICIPANTS/MATERIALS, SETTING, METHOD: Arab couples, with a female age between 18-40 years, body mass index ≤30 kg/m2, at least 10 cumulus oocyte complexes (COCs) following oocyte retrieval (OR) and normal semen concentration and motility (WHO) in the fresh ejaculate on the day of OR, were eligible for the study. Half of the sibling oocytes were assigned to conventional IVF, and the other half were assigned to ICSI. All embryos were cultured in a time-lapse imaging system in Global Total LP media. Blastocysts were subjected to trophectoderm biopsy on Day 5, 6 or 7 and next-generation sequencing (NGS) to determine blastocyst ploidy status. The primary objective was to determine the euploid rate in blastocysts from sibling oocytes. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 568 COCs were randomly allocated between IVF (n = 283; 9.4 ± 4.0) and ICSI (n = 285; 9.5 ± 4.1). While the incidence of normal fertilisation per cycle (6.1 ± 3.8 (64.0%) vs 6.3 ± 3.5 (65.4%); P = 0.609) was distributed equally between IVF and ICSI, the degeneration rate (0.1 ± 0.3 vs 0.7 ± 0.8; P = 0.0003) was significantly higher after ICSI and the incidence of abnormal fertilisation (≥3 pronuclei) was significantly higher after IVF (0.9 ± 1.2 vs 0.2 ± 0.4; P = 0.005). For all fertilised oocytes, there were no differences in the number of good-quality embryos on Day 3 (74% vs 78%; P = 0.467), nor in the blastulation rate on Day 5 (80.4% vs 70.8%; P = 0.076). The total number of blastocysts biopsied per cycle on Days 5, 6 and 7 was not significantly different between IVF or ICSI (4.0 ± 2.8 vs 3.9 ± 2.5; P = 0.774). With euploid rates of 49.8 and 44.1% (P = 0.755; OR: 1.05664 [0.75188-1.48494), respectively, there was no significant difference identified between IVF and ICSI (2.0 ± 1.8 vs 1.9 ± 1.7; P = 0.808) and all couples had at least one euploid blastocyst available for transfer. When considering only euploid blastocysts, the male/female ratio was 61/39 in IVF and 43/57 in ICSI (P = 0.063). LIMITATIONS, REASON FOR CAUTION: This is a pilot study with a limited patient population of 30 couples (and 568 COCs) with a normal ovarian response. The results of our study should not be extrapolated to other patient populations. WIDER IMPLICATIONS OF THE FINDINGS: It is safe to apply conventional IVF in couples with non-male factor infertility undergoing PGT-A. STUDY FUNDING/COMPETING INTEREST(S): No funding was obtained. There are no competing interests. TRIAL REGISTRATION NUMBER: NCT03708991.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. De Munck N, El Khatib I, Abdala A, et al. Intracytoplasmic sperm injection is not superior to conventional IVF in couples with non-male factor infertility and preimplantation genetic testing for aneuploidies (PGT-A). Hum Reprod. 2020. PMID: 32086522. doi:10.1093/humrep/deaa002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。